Frequently Asked Questions on MammoScreen

Frequently Asked Questions on MammoScreen

MammoScreen clinical study will enroll 10.000 women already included in regional or national breast cancer screening programmes in Italy, Spain, Switzerland, Poland and Portugal. Ten clinical trial centers overall will be involved in the study.
Women that fulfill the requirements to join the clinical trial will be thoroughly informed about all its aspects and asked to sign and informed consent before proceeding with the examination with MammoWave.
The only way to join the trial is that you fall within the aforementioned screening programmes and you are appointed to one of the clinical trial centers carrying out the study. In this case, at the moment of your regular screening, you might be asked to take part to the MammoScreen study. The study cannot enroll spontaneous applications.

You can follow MammoScreen on Twitter, Facebook and LinkedIn, or you can subscribe to the newsletter to be always updated.

MammoWave is totally safe, as it uses very low power microwave signals to perform the examination which are completely harmless. The power of these microwaves is 100 fold less than the radiofrequency of a mobile phone.

The examination takes approximately 8 minutes per breast.

Breast density reflects the amount of fibrous and glandular tissue in a woman’s breasts compared with the amount of fatty tissue in the breasts. The breast density can be measured from mammography. Women whose breasts are evenly dense throughout (about 40% of women) or are extremely dense (about 10% of women) are said to have high-density or dense breasts. Moreover, studies have demonstrated that these women have a higher chance to develop breast cancer.

Due to the composition of dense breast, standard mammography may fail in detecting cancers that hide in these tissues. On the other hand, MammoWave is effective also on dense breasts, and could help in the early detection of breast cancers that could be otherwise invisible to standard mammography.

Women in the age between 30 and 49 account for 30% of breast cancers in Europe. Yet this population is often left out of the current screening programs. Why is it so? Standard mammography employs X-rays, which, after recurrent exposure, might pose a risk to healthy women. Thus, considering also the low probability to develop breast cancer at a young age, performing standard mammography every two years in younger women is generally avoided, as it could be detrimental rather than beneficial.

MammoWave could revolutionize screening programmes because it is totally safe and can be employed to screen women of any age without frequency limitations, thus allowing for the expansion of the age range in breast screening programmes.

MammoScreen aims at being as patient centric as possible and making every woman the subject, rather than the object, of the screening process.
MammoWave, the medical device studied in the project, is designed to be comfortable and female-friendly. No compression of the breast, no pain, no discomfort occur during MammoWave examination, helping women to have a better patient experience and increasing compliance and adherence to screening programmes.

Besides, MammoScreen will develop a modern, patient-facing app, to put patients and their needs at the center of the process. This ensures that they can easily manage their appointments and access information regarding the breast screening scan/process, and have their results swiftly delivered via the app, giving them control and agency during the process. This will be integrated with the clinical web-portal, which will streamline the entire breast screening process, enabling more people to regularly check breast health.

You can contact the manufacturer of MammoWave, and partner of MammoScreen, Umbria Bioengineering Technologies.

You can contact the manufacturer of MammoWave, and partner of MammoScreen, Umbria Bioengineering Technologies.